Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-β (DAV + IFN-β therapy) into malignant melanoma

Journal of Dermatology

Volumn 25, Issue 9, 1998, Pages 569-572

  Umeda, Tadashi ^a   Aoki, Kazuhiro ^a   Yokoyama, Akiko ^a   Ohara, Hiroyuki ^a   Hayashi, Ohmi ^a   Tanaka, Kazuyuki ^a   Nishioka, Kiyoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Combination adjuvant chemotherapy; Malignant melanoma; Natural killer activity

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; NIMUSTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LEUKOCYTE COUNT; MALE; MELANOMA; NATURAL KILLER CELL; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-CD8 RATIO; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; NIMUSTINE; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TREATMENT OUTCOME; VINCRISTINE;

EID: 0031789129     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Yamamoto A, Ishihara K: Clinical study of DAV + IFN-β therapy (combination adjuvant therapy with intravenous DTIC, ACNU and VCR, and local injection of IFN-β) for malignant melanoma, Int J Immunotherapy, 12: 73-78, 1996.
2. Fukuzawa K, Horikoshi T: Inhibitory effect of human fibroblast interferon (HuIFN-β) on the growth and invasive potential of cultured human melanoma cells in vitro, Br J Dermatol, 126: 324-330, 1992.
3. Yamamoto A, Mori S: Effect of combination administration of IFN-β in initial treatment of malignant melanoma, Skin Cancer, 4: 8-12, 1989.
4. Fierlbeck G, Ulmer A, Schreiner T, Stroebel W, Schiebel U, Brzoska J: Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma, J Interferon Res, 16: 777-781, 1996.